BPI-9016M

DRUG2 trials

Sponsors

Betta Pharmaceuticals Co., Ltd.

Conditions

Non-small Cell Lung CancerSolid Tumors

Phase 1

Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors

CompletedNCT02478866

Betta Pharmaceuticals Co., Ltd.Solid Tumors

Start: 2015-08-11End: 2017-11-30Updated: 2021-09-16

Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC

Betta Pharmaceuticals Co., Ltd.Non-small Cell Lung Cancer

Start: 2017-03-01End: 2024-11-30Target: 80Updated: 2021-09-13

Related Papers

Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study

BMC Cancer2023-04-117 citations

First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer.

2020-01-1618 citations

BPI-9016M, a novel c-Met inhibitor, in pretreated advanced solid tumor: Results from a first-in-human, phase I, dose-escalation study

Annals of Oncology2018-10-01

BPI-9016M, a novel c-Met inhibitor, in pretreated advanced solid tumor: Results from a first-in-human, phase I, dose-escalation study.

Journal of Clinical Oncology2018-05-20